App aims to tame chemo side effects in breast cancer
NCT ID NCT05425550
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. However, the study was terminated early, so we have limited data on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
medidux™ digital health application
What this could lead to
If it works, this app could help patients and doctors better track and manage chemotherapy side effects, potentially reducing severe complications.
What could go wrong
The study was terminated early, so results are limited. The app is a supportive tool, not a treatment, and its benefit over standard care is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seespital Horgen-Onkologie
Horgen, 8810, Switzerland